A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Zwart, Wilbert ^a,b   Koornstra, Rutger ^a   Wesseling, Jelle ^a   Rutgers, Emiel ^a   Linn, Sabine ^a   Carroll, Jason S ^b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; HISTONE; MESSENGER RNA; TRANSCRIPTION FACTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CELL COUNT; CELL PROLIFERATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORE NEEDLE BIOPSY; DISEASE ASSOCIATION; DOWN REGULATION; ESTROGEN GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEEDLE BIOPSY; ONCOGENE; OUTCOME ASSESSMENT; PROTEIN BINDING; PROTEIN DETERMINATION; SEQUENCE ANALYSIS; UPREGULATION;

BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; ESTROGEN RECEPTOR ALPHA; HUMANS; MCF-7 CELLS; PROTEIN BINDING; SEQUENCE ANALYSIS;

EID: 84875835782     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-232     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
3. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95(5):353-361. 10.1093/jnci/95.5.353, 12618500.
4. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006, 98(10):671-680. 10.1093/jnci/djj185, 16705121.
5. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004, 5(6):597-605. 10.1016/j.ccr.2004.05.016, 15193262.
6. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, Hill AD, Young LS. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15(6):2098-2106.
7. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96(12):926-935. 10.1093/jnci/djh166, 15199112.
8. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61(12):4744-4749.
9. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010, 24(19):2219-2227. 10.1101/gad.1944810, 2947773, 20889718.
10. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011, 43(1):27-33. 10.1038/ng.730, 3024537, 21151129.
11. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481(7381):389-393. 3272464, 22217937.
12. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462(7269):58-64. 10.1038/nature08497, 2774924, 19890323.
13. Zwart W, Theodorou V, Kok M, Canisius S, Linn S, Carroll JS. Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. EMBO J 2011, 30(23):4764-4776. 10.1038/emboj.2011.368, 3243612, 22002538.
14. Adli M, Zhu J, Bernstein BE. Genome-wide chromatin maps derived from limited numbers of hematopoietic progenitors. Nat Methods 2010, 7(8):615-618. 10.1038/nmeth.1478, 2924612, 20622861.
15. Shankaranarayanan P, Mendoza-Parra MA, Walia M, Wang L, Li N, Trindade LM, Gronemeyer H. Single-tube linear DNA amplification (LinDA) for robust ChIP-seq. Nat Methods 2011, 8(7):565-567. 10.1038/nmeth.1626, 21642965.
16. O'Neill LP, VerMilyea MD, Turner BM. Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 2006, 38(7):835-841. 10.1038/ng1820, 16767102.
17. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 2009, 48(3):240-248. 10.1016/j.ymeth.2009.03.001, 19275939.
18. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38(11):1289-1297. 10.1038/ng1901, 17013392.
19. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123(3):725-731. 10.1007/s10549-009-0674-9, 20020197.
20. Adli M, Bernstein BE. Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq. Nat Protoc 2011, 6(10):1656-1668. 10.1038/nprot.2011.402, 21959244.
21. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008, 9(9):R137. 10.1186/gb-2008-9-9-r137, 2592715, 18798982.
22. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y, Xu K, Ni M, Lupien M. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010, 42(4):343-347. 10.1038/ng.545, 2932437, 20208536.
23. Ji X, Li W, Song J, Wei L, Liu XS. CEAS: cis-regulatory element annotation system. Nucleic Acids Res 2006, 34(Web Server issue):W551-W554. 1538818, 16845068.
24. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ 2002, 325(7365):648-651. 10.1136/bmj.325.7365.648, 12269316.